Ketamine in Preventing Delirium in Patients with Head and Neck Cancer after Surgery
- With otolaryngeal cancer receiving surgery with general anesthesia * Please note we are purposefully including patients with higher predisposition to delirium as we are investigating potential preventive strategies for this diagnosis of multiple etiologies; patients at higher risk of delirium (e.g., advanced age, chronic hypertension) will be included in our study; additionally, other common risk factors that exist in this patient population (e.g., alcohol or nicotine use) are thought to contribute to delirium postoperatively
- Competent to provide informed consent
- Emergency surgery
- Monitored anesthesia care (i.e., regional anesthesia alone without plans for general anesthesia)
- Surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement
- Poor health literacy
- Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded
- Pregnant or lactating patients
- Patients in active alcohol withdrawal
- Patients with chronic pain who are taking buprenorphine
I. Optimize our intraoperative treatment protocol for head and neck cancer patients to reduce the incidence of delirium and associated postoperative cognitive dysfunction.
I. Determine the dose response relationship for intraoperative ketamine and delirium reduction.
II. Determine if a single dose of ketamine will reduce post-operative pain and opioid requirements.
III. Determine if raw electroencephalography (EEG) data can predict postoperative delirium during general anesthesia.
IV. Evaluate length of intensive care unit (ICU) and length of hospital stay (done by medical chart review).
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive lower dose ketamine intravenously (IV) before surgery.
ARM II: Patients receive higher dose ketamine IV before surgery.
ARM III: Patients receive placebo IV before surgery.
After completion of study treatment, patients are followed up 2-6 weeks post-surgery.
Trial Phase Phase IV
Trial Type Treatment
Emory University Hospital / Winship Cancer Institute
- Primary ID EU3268-16
- Secondary IDs NCI-2017-00172, IRB00086609
- Clinicaltrials.gov ID NCT03040024